ATE368225T1 - Verwendung von antikörpern gegen spezifische mhc- peptidkomplexe - Google Patents

Verwendung von antikörpern gegen spezifische mhc- peptidkomplexe

Info

Publication number
ATE368225T1
ATE368225T1 AT01974130T AT01974130T ATE368225T1 AT E368225 T1 ATE368225 T1 AT E368225T1 AT 01974130 T AT01974130 T AT 01974130T AT 01974130 T AT01974130 T AT 01974130T AT E368225 T1 ATE368225 T1 AT E368225T1
Authority
AT
Austria
Prior art keywords
antibodies against
peptide complexes
against specific
specific mhc
mhc peptide
Prior art date
Application number
AT01974130T
Other languages
English (en)
Inventor
Petrus Steenbakkers
Original Assignee
Organon Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Organon Nv filed Critical Organon Nv
Application granted granted Critical
Publication of ATE368225T1 publication Critical patent/ATE368225T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/866—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody fragment, e.g. fab', fab, fv, fc, heavy chain or light chain
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rehabilitation Therapy (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT01974130T 2000-08-14 2001-08-08 Verwendung von antikörpern gegen spezifische mhc- peptidkomplexe ATE368225T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00202844 2000-08-14

Publications (1)

Publication Number Publication Date
ATE368225T1 true ATE368225T1 (de) 2007-08-15

Family

ID=8171913

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01974130T ATE368225T1 (de) 2000-08-14 2001-08-08 Verwendung von antikörpern gegen spezifische mhc- peptidkomplexe

Country Status (14)

Country Link
US (1) US7320873B2 (de)
EP (1) EP1319184B1 (de)
JP (1) JP2004506901A (de)
CN (1) CN1305906C (de)
AR (1) AR033832A1 (de)
AT (1) ATE368225T1 (de)
AU (2) AU9373501A (de)
BR (1) BR0113213A (de)
CA (1) CA2415353A1 (de)
DE (1) DE60129572T2 (de)
ES (1) ES2290171T3 (de)
IL (2) IL154000A0 (de)
MX (1) MXPA03001391A (de)
WO (1) WO2002014870A2 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006508014A (ja) 2001-07-24 2006-03-09 イエール・ユニバーシテイ キチナーゼおよびキチナーゼ様分子、ならびに炎症性疾患に関する方法、組成物およびキット
AU2005247950B2 (en) * 2004-05-27 2012-02-02 Receptor Logic, Inc. Antibodies as T cell receptor mimics, methods of production and uses thereof
CA2662798A1 (en) * 2005-09-07 2007-03-15 Receptor Logic, Ltd. Antibodies as t cell receptor mimics, methods of production and uses thereof
KR20090117878A (ko) * 2007-01-19 2009-11-13 카이 파마슈티컬즈 통증의 완화를 위한 엡실론 억제제 화합물의 사용 방법
WO2009151487A1 (en) * 2008-06-13 2009-12-17 Receptor Logic, Inc. Methods of assaying vaccine potency
EP2437780B1 (de) * 2009-06-04 2016-03-23 The Regents of the University of Colorado Therapeutische zusammensetzungen und verfahren zur prävention von autoimmunkrankheiten
EP2544694B1 (de) * 2010-03-02 2018-10-31 Novelmed Therapeutics, Inc. Verfahren zur hemmung von durch alternative pfade vermittelten störungen mit antikörpern gegen properdin zur hemmung von c5-interaktionen mit properdin
US9695410B2 (en) 2010-07-15 2017-07-04 Technion Research & Development Foundation Limited Isolated high affinity entities with T-cell receptor like specificity towards native complexes of MHC class II and glutamic acid decarboxylase (GAD) autoantigenic peptides
CA2805478A1 (en) * 2010-07-15 2012-01-19 Technion Research & Development Foundation Ltd. Isolated high affinity entities with t-cell receptor like specificity towards native complexes of mhc class ii and diabetes-associated autoantigenic peptides
EP2619579B1 (de) * 2010-09-21 2016-12-07 The General Hospital Corporation Diagnostische immunreaktivitätstests mit dem menschlichen endothelzellenwachstumsfaktor
SG192941A1 (en) 2011-02-25 2013-09-30 Merck Sharp & Dohme Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
US9629848B2 (en) 2011-05-26 2017-04-25 The Regents Of The University Of Colorado, A Body Corporate Compounds that modulate autoimmunity and methods of using the same
CA2887050A1 (en) 2012-10-04 2014-04-10 Novelmed Therapeutics, Inc. Alternative pathway specific antibodies for treating hemolytic diseases
EA035419B9 (ru) 2014-05-29 2020-08-07 Мэкроудженикс, Инк. Триспецифичные связывающие молекулы и способы их применения
EP3247384B1 (de) 2015-01-14 2023-10-04 The Regents of the University of Colorado, a body corporate In vitro verfahren zur diagnose von typ-1-diabetes mit insulinmimotopen
WO2017165508A1 (en) 2016-03-24 2017-09-28 Im Therapeutics Methods of treating autoimmune disease
AU2018224094B2 (en) 2017-02-24 2025-04-17 Macrogenics, Inc. Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof
US11052060B2 (en) 2018-02-12 2021-07-06 The Regents Of The University Of Colorado, A Body Corporate Compounds and methods for treating autoimmunity
US11013707B2 (en) 2018-03-23 2021-05-25 The Regents Of The University Of Colorado, A Body Corporate Administration of oral methyldopa
CN111423504B (zh) * 2020-04-17 2021-03-26 安徽高安生物医学科技有限公司 黑色素瘤特异性抗原肽、肽复合物以及人工抗原呈递细胞
CN115960239B (zh) * 2023-01-03 2025-10-17 陕西脉元生物科技有限公司 特异性识别hcgp-39的单克隆抗体及其制备方法和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0488470T3 (da) 1990-11-26 1997-12-22 Akzo Nobel Nv Fremgangsmåde til fremstilling af antistoffer
WO1995002188A1 (en) * 1993-07-12 1995-01-19 The Regents Of The University Of California Assay for ykl-40 as a marker for degradation of mammalian connective tissue matrices
CA2164498C (en) * 1993-07-09 2007-09-11 Paul A. Price Assay for ykl-40 as a marker for degradation of mammalian connective tissue matrices
DE59709363D1 (de) * 1996-09-18 2003-03-27 Gerhild Wildner Peptide als diagnostikum und therapeutikum für autoimmunerkrankungen
IL122233A (en) 1996-12-06 2001-04-30 Akzo Nobel Nv Method of generating monoclonal antibodies to cell wall and pharmaceutical preparations and diagnostic agents containing them

Also Published As

Publication number Publication date
MXPA03001391A (es) 2004-05-04
DE60129572D1 (de) 2007-09-06
JP2004506901A (ja) 2004-03-04
CN1447919A (zh) 2003-10-08
AR033832A1 (es) 2004-01-07
DE60129572T2 (de) 2008-04-17
AU2001293735B2 (en) 2006-05-25
US7320873B2 (en) 2008-01-22
ES2290171T3 (es) 2008-02-16
AU9373501A (en) 2002-02-25
BR0113213A (pt) 2003-07-08
IL154000A0 (en) 2003-07-31
EP1319184B1 (de) 2007-07-25
WO2002014870A2 (en) 2002-02-21
CN1305906C (zh) 2007-03-21
IL154000A (en) 2010-02-17
CA2415353A1 (en) 2002-02-21
WO2002014870A3 (en) 2002-08-15
US20040137514A1 (en) 2004-07-15
EP1319184A2 (de) 2003-06-18

Similar Documents

Publication Publication Date Title
ATE368225T1 (de) Verwendung von antikörpern gegen spezifische mhc- peptidkomplexe
EP1294513A4 (de) Lokalisationsspezifische kovalente biokonjugation von proteinen
DE60124863D1 (de) Gegen menschliche interleukin-1-beta gerichtete rekombinante antikörper
DE60041505D1 (de) Inzektizide proteinen von bacillus thuringiensis
DE50012379D1 (de) Verwendung von nanoskaligen antischuppenwirkstoffen
DK1390389T3 (da) Cripto-blokerende antistoffer og anvendelser deraf
DE69932650D1 (de) Zementierkopf
IL164021A (en) Anti-alphavbeta6 antibodies and pharmaceutical compositions containing the same
DE60235989D1 (de) Antikörper gegen opgl
ATE357459T1 (de) Antikörper gegen mensliches il-12
IS7499A (is) Mennsk mótefni gegn beta-amýloíðpeptíðum
EP1499352A4 (de) Rekombinante anti-interleukin-9-antikörper
DE50212455D1 (de) Verwendung von Dimerdiolen
DE60210864D1 (de) Modifiziertes fluoreszentes Protein
DE60126814D1 (de) Inhalation von stickoxid
NO20034588D0 (no) Fremgangsmåter og midler for anvendelse av HLA-DQ- restringerte T-cellereseptorer og HLA-DQ-bindende prolaminderiverte peptider
EE200300569A (et) CD44v6-spetsiifilised antikehad
ATA143099A (de) Satz von schmuckstücken
ATE259825T1 (de) Hemihydrat von 16.alpha.-bromoepiandrosterone
ATA192799A (de) Neue verwendung von antikörpern als impfstoffe
DE60006634D1 (de) Fluoreszente materialen
EP1197556A4 (de) NüTZLICHE POLYPEPTIDE
FR2791258B1 (fr) Composition amincissante
FR2791348B1 (fr) POLYPEPTIDE Npt2B
EP1359932A4 (de) Tip39 polypeptide

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties